Evidence map›Paper›PMID 27314328›Full record

ArticleInternational journal of molecular sciences2016

The Effect of Analogues of 1α,25-Dihydroxyvitamin D₂ on the Regrowth and Gene Expression of Human Colon Cancer Cells Refractory to 5-Fluorouracil.

Jacek Neska, Paweł Swoboda, Małgorzata Przybyszewska, Agnieszka Kotlarz, Narasimha Rao Bolla, Joanna Miłoszewska, Monika Anna Grygorowicz, Andrzej Kutner, Sergiusz Markowicz

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Vitamins D: Relationship between Structure and Biological Activity.International journal of molecular sciences · 2018
    Review
  5. Adipose tissue inflammation andClinical epigenetics · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jacek NeskaDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. jacek.neska91@gmail.com.
Paweł SwobodaDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. pswoboda@o2.pl.
Małgorzata PrzybyszewskaDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. magip@coi.waw.pl.
Agnieszka KotlarzDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. akotlarz@coi.waw.pl.
Narasimha Rao BollaChemistry Department, Pharmaceutical Research Institute, 8 Rydygiera, 01-793 Warsaw, Poland. n.bolla@ifarm.eu.
Joanna MiłoszewskaDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. joannam@coi.waw.pl.
Monika Anna GrygorowiczDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. m.a.grygorowicz@gmail.com.
Andrzej KutnerPharmacology Department, Pharmaceutical Research Institute, 8 Rydygiera, 01-793 Warsaw, Poland. a.kutner@ifarm.eu.
Sergiusz MarkowiczDepartment of Immunology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen, 02-781 Warsaw, Poland. sergiusz.markowicz@coi.pl.
The Maria Sklodowska-Curie National Research Institute of Oncology · PLInstytut Farmaceutyczny · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the capacity of hypocalcemic analogues of 1α,25-dihydroxyvitamin D₂ (1,25D2) and 1α,25-dihydroxyvitamin D₃ (1,25D3) to inhibit regrowth and regulate the stemness-related gene expression in colon cancer cells undergoing renewal after exposure to 5-fluorouracil (5-FU). All of the tested analogues of 1,25D2 equally potently decreased the clonogenicity and the proliferative activity of HT-29 cells which survived the exposure to 5-FU, but differently regulated gene expression of these cells during their renewal. 1,25D2 and analogues (PRI-1907 and PRI-1917), as well as 1,25D3 and analogue PRI-2191, decreased the relative expression level of several stemness-related genes, such as NANOG, OCT3/4, PROM1, SOX2, ALDHA1, CXCR4, in HT-29/5-FU cells during their renewal, in comparison to untreated HT-29/5-FU cells. The other 1,25D2 analogues (PRI-1906 and PRI-1916) were not capable of downregulating the expression of these stemness-related genes as the analogues PRI-1907 and PRI-1917 did. All of the tested vitamin D analogues upregulated CDH1, the gene encoding E-cadherin associated with epithelial phenotype. Out of the series of analogues studied, side-chain branched analogues of 1,25D2 (PRI-1907, PRI-1917) and the analogue of 1,25D3 (PRI-2191) might be used to target cancer cells with stem-like phenotypes that survive conventional chemotherapy.

Indexed as

Antineoplastic AgentsCalcitriolCell ProliferationColonic NeoplasmsDown-RegulationDrug Resistance, NeoplasmFluorouracilGene Expression Regulation, NeoplasticHT29 CellsHumansVitaminsAntineoplastic AgentsCalcitriolFluorouracilVitamins1α,25-dihydroxyvitamin D21α,25-dihydroxyvitamin D3cancer and vitamin Dcancer stem cellcolorectal cancerHT-29 cell linevitamin D analoguesvitamin D and chemotherapy

Identifiers

PMID27314328
PMCPMC4926437
OpenAlexW2426907224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.